Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still...

Descripción completa

Detalles Bibliográficos
Autores principales: Martino, Massimo, Naso, Virginia, Loteta, Barbara, Canale, Filippo Antonio, Pugliese, Marta, Alati, Caterina, Musuraca, Gerardo, Nappi, Davide, Gaimari, Anna, Nicolini, Fabio, Mazza, Massimiliano, Bravaccini, Sara, Derudas, Daniele, Martinelli, Giovanni, Cerchione, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657035/
https://www.ncbi.nlm.nih.gov/pubmed/36362130
http://dx.doi.org/10.3390/ijms232113332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657035/
https://www.ncbi.nlm.nih.gov/pubmed/36362130
http://dx.doi.org/10.3390/ijms232113332

Ejemplares similares